GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Graham Number

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Graham Number : $N/A (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-04-27), the stock price of Teva Pharmaceutical Industries is $13.81. Teva Pharmaceutical Industries's graham number for the quarter that ended in Dec. 2023 was $N/A. Therefore, Teva Pharmaceutical Industries's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Teva Pharmaceutical Industries's Graham Number or its related term are showing as below:

TEVA's Price-to-Graham-Number is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Teva Pharmaceutical Industries Graham Number Historical Data

The historical data trend for Teva Pharmaceutical Industries's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Graham Number Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Teva Pharmaceutical Industries's Graham Number

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's Price-to-Graham-Number Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Price-to-Graham-Number falls into.



Teva Pharmaceutical Industries Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Teva Pharmaceutical Industries's Graham Number for the fiscal year that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*-13.432*2.56)
=N/A

Teva Pharmaceutical Industries's Graham Number for the quarter that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*-13.432*2.56)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Teva Pharmaceutical Industries  (NYSE:TEVA) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Teva Pharmaceutical Industries's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2023 )
=13.81/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Teva Pharmaceutical Industries Graham Number Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX